ITALY PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) MARKET ANALYSIS

Market Challenges And Opportunities

Italy Peptide Receptor Radionuclide Therapy (PRRT) Market - Restraints

High cost associated with cancer treatment, which include diagnosis and therapeutic treatment, is a major factor that is expected to restrain growth of the market. For instance, as per the Economist Intelligence Unit Limited’s 2016 report, lung cancer treatment cost has become a burden on the economy in Italy. In 2013, it was estimated that total cost for treatment of lung cancer reached around US$ 18.31 billion.

Currently, only one approved PRRT drug is available in the Italy market, and is used in the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumor (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. Therefore, lack of availability of different drugs is another major factor restraining growth of the market.

Moreover, high cost of treatment is expected to restrain growth of the market. For instance, Novartis Company’s drug, Lutathera, is priced at US$ 99,900 for a full course of treatment comprising four infusions.

Increasing incidence of pancreatic cancer, as well as availability of reimbursement for cancer drug is another factor contributing to the market growth.